Literature DB >> 33617509

A Histone Acetylation Modulator Gene Signature for Classification and Prognosis of Breast Cancer.

Mengping Long1, Wei Hou1, Yiqiang Liu1, Taobo Hu2.   

Abstract

Regulators of histone acetylation are promising epigenetic targets for therapy in breast cancer. In this study, we comprehensively analyzed the expression of histone acetylation modulator genes in breast cancer using TCGA data sources. A gene signature composed of eight histone acetylation modulators (HAMs) was found to be effective for the classification and prognosis of breast cancers, especially in the HER2-enriched and basal-like molecular subtypes. The eight genes consist of two histone acetylation writers (GTF3C4 and CLOCK), two erasers (HDAC2 and SIRT7) and four readers (BRD4, BRD7, SP100, and BRWD3). Both histone acetylation writer genes and eraser genes were found to be differentially expressed between the two groups indicating a close relationship exists between overall histone acetylation level and prognosis of breast cancer in HER2-enriched and basal-like breast cancer.

Entities:  

Keywords:  breast cancer; gene signature; histone acetylation; intrinsic subtype; prognosis

Year:  2021        PMID： 33617509      PMCID： PMC7985767          DOI： 10.3390/curroncol28010091

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


  36 in total

Review 1.  Readers of histone modifications.

Authors:  Miyong Yun; Jun Wu; Jerry L Workman; Bing Li
Journal:  Cell Res       Date:  2011-03-22       Impact factor: 25.617

2.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

3.  Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.

Authors:  Junko Suzuki; Yunn-Yi Chen; Gary K Scott; Sandy Devries; Koei Chin; Christopher C Benz; Frederic M Waldman; E Shelley Hwang
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

4.  CancerSubtypes: an R/Bioconductor package for molecular cancer subtype identification, validation and visualization.

Authors:  Taosheng Xu; Thuc Duy Le; Lin Liu; Ning Su; Rujing Wang; Bingyu Sun; Antonio Colaprico; Gianluca Bontempi; Jiuyong Li
Journal:  Bioinformatics       Date:  2017-10-01       Impact factor: 6.937

Review 5.  Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review.

Authors:  Agata Szymiczek; Amna Lone; Mohammad R Akbari
Journal:  Clin Genet       Date:  2020-12-28       Impact factor: 4.438

6.  Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.

Authors:  Berit Maria Müller; Lisa Jana; Atsuko Kasajima; Annika Lehmann; Judith Prinzler; Jan Budczies; Klaus-Jürgen Winzer; Manfred Dietel; Wilko Weichert; Carsten Denkert
Journal:  BMC Cancer       Date:  2013-04-30       Impact factor: 4.430

7.  A flexible R package for nonnegative matrix factorization.

Authors:  Renaud Gaujoux; Cathal Seoighe
Journal:  BMC Bioinformatics       Date:  2010-07-02       Impact factor: 3.169

8.  Chronic circadian disruption modulates breast cancer stemness and immune microenvironment to drive metastasis in mice.

Authors:  Eva Hadadi; William Taylor; Xiao-Mei Li; Yetki Aslan; Marthe Villote; Julie Rivière; Gaelle Duvallet; Charlotte Auriau; Sandrine Dulong; Isabelle Raymond-Letron; Sylvain Provot; Annelise Bennaceur-Griscelli; Hervé Acloque
Journal:  Nat Commun       Date:  2020-06-24       Impact factor: 14.919

9.  Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment.

Authors:  Zhongyi Hu; Junzhi Zhou; Junjie Jiang; Jiao Yuan; Youyou Zhang; Xuepeng Wei; Nicki Loo; Yueying Wang; Yutian Pan; Tianli Zhang; Xiaomin Zhong; Meixiao Long; Kathleen T Montone; Janos L Tanyi; Yi Fan; Tian-Li Wang; Ie-Ming Shih; Xiaowen Hu; Lin Zhang
Journal:  Nat Commun       Date:  2019-02-13       Impact factor: 14.919

10.  Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome.

Authors:  Somaia E Elsheikh; Andrew R Green; Emad A Rakha; Des G Powe; Rabab A Ahmed; Hilary M Collins; Daniele Soria; Jonathan M Garibaldi; Claire E Paish; Amr A Ammar; Matthew J Grainge; Graham R Ball; Magdy K Abdelghany; Luisa Martinez-Pomares; David M Heery; Ian O Ellis
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701
View more
  3 in total

1.  Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer.

Authors:  Mengping Long; Hongjun Liu; Jinbo Wu; Shu Wang; Xin Liao; Yiqiang Liu; Taobo Hu
Journal:  Comput Math Methods Med       Date:  2022-07-09       Impact factor: 2.809

2.  Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores.

Authors:  Taobo Hu; Yan Chen; Yiqiang Liu; Danhua Zhang; Jiankang Pan; Mengping Long
Journal:  BMC Med Res Methodol       Date:  2021-05-22       Impact factor: 4.615

3.  AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status.

Authors:  Mengping Long; Chong You; Qianqian Song; Lina X J Hu; Zhaorong Guo; Qian Yao; Wei Hou; Wei Sun; Baosheng Liang; Xiaohua Zhou; Yiqiang Liu; Taobo Hu
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.